Home • Search • Translate
From Wikipedia, the free encyclopedia
Cerlapirdine
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • N,N-dimethyl-3-[(3-naphthalen-1-ylsulfonyl-2H-indazol-5-yl)oxy]propan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H23N3O3S
Molar mass409.50 g·mol−1
3D model ( JSmol)
  • CN(C)CCCOc4ccc3[nH]nc(S(=O)(=O)c1cccc2ccccc12)c3c4
  • InChI=1S/C22H23N3O3S/c1-25(2)13-6-14-28-17-11-12-20-19(15-17)22(24-23-20)29(26,27)21-10-5-8-16-7-3-4-9-18(16)21/h3-5,7-12,15H,6,13-14H2,1-2H3,(H,23,24)
  • Key:NXQGEDVQXVTCDA-UHFFFAOYSA-N

Cerlapirdine ( USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/ Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. [1] In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, [2] but no further development has occurred since 2011. [3]

It exerts its effects by acting as a selective 5-HT6 receptor antagonist. [1]

See also

References

  1. ^ a b Codony X, Vela JM, Ramírez MJ (February 2011). "5-HT(6) receptor and cognition". Current Opinion in Pharmacology. 11 (1): 94–100. doi: 10.1016/j.coph.2011.01.004. hdl: 10171/18451. PMID  21330210.
  2. ^ Franco Borsini (2011). International review of neurobiology: Pharmacology of 5-HT6 receptors. Part 2. Academic Press. p. 5. ISBN  978-0-12-385902-0. Retrieved 25 October 2011.
  3. ^ Drug Profile: Cerlapirdine
Retrieved from " https://en.wikipedia.org/?title=Cerlapirdine&oldid=1120768438"
From Wikipedia, the free encyclopedia
Cerlapirdine
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • N,N-dimethyl-3-[(3-naphthalen-1-ylsulfonyl-2H-indazol-5-yl)oxy]propan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H23N3O3S
Molar mass409.50 g·mol−1
3D model ( JSmol)
  • CN(C)CCCOc4ccc3[nH]nc(S(=O)(=O)c1cccc2ccccc12)c3c4
  • InChI=1S/C22H23N3O3S/c1-25(2)13-6-14-28-17-11-12-20-19(15-17)22(24-23-20)29(26,27)21-10-5-8-16-7-3-4-9-18(16)21/h3-5,7-12,15H,6,13-14H2,1-2H3,(H,23,24)
  • Key:NXQGEDVQXVTCDA-UHFFFAOYSA-N

Cerlapirdine ( USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/ Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. [1] In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, [2] but no further development has occurred since 2011. [3]

It exerts its effects by acting as a selective 5-HT6 receptor antagonist. [1]

See also

References

  1. ^ a b Codony X, Vela JM, Ramírez MJ (February 2011). "5-HT(6) receptor and cognition". Current Opinion in Pharmacology. 11 (1): 94–100. doi: 10.1016/j.coph.2011.01.004. hdl: 10171/18451. PMID  21330210.
  2. ^ Franco Borsini (2011). International review of neurobiology: Pharmacology of 5-HT6 receptors. Part 2. Academic Press. p. 5. ISBN  978-0-12-385902-0. Retrieved 25 October 2011.
  3. ^ Drug Profile: Cerlapirdine
Retrieved from " https://en.wikipedia.org/?title=Cerlapirdine&oldid=1120768438"

Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook




Top Of Page

Home • Search • Translate

© CSE